Effect of Quassia wood on Diabetes

Phase 1

Completed

Conditions: Health Condition 1: null- Patients suffering from Prameha ( DiabetesMellitus )

Registration Number: CTRI/2014/07/004775

Lead Sponsor: IPGTRA Gujarat Ayurved University

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Completed

Sex: Not specified

Target Recruitment: 100

Inclusion Criteria

INCLUSION CRITERIA

Age between 40 years to 70 years

Patients having chief and associated complaints of Apathyanimittaja Prameha

Known patient of Type II diabetes mellitus and also the patients preliminarily diagnosed Type II diabetes mellitus on the basis of signs and symptoms of the disease will be confirmed by FBS and PPBS

DIAGNOSIS CRITERIA

Standard criteria of National Diabetes Data group and the World Health Organization for Diabetes Mellitus will be adopted as follow

Symptoms of diabetes Mellitus

Random blood glucose concentration greater than 200 mg dLOR

Fasting blood glucose greater than 126mgdLOR

Two hours blood glucose greater than 200 mgdL during an oral glucose tolerance test Adopted by American Diabetic Association

Exclusion Criteria

EXCLUSION CRITERIA

Age below 40 years & above 70 years

Patients of Sahaja Prameha and having bala and dhatukshaya and Type I diabetes mellitus

Patients suffering from Malignant and accelerated hypertension CVS disorder CAD Pregnant woman and planning to be pregnant within six months Lactating mother Secondary diabetes mellitus diabetic ketosis CNS disorder eg encephalopathy

Patient undergoing regular treatment for any other severe illness and also patients suffering from tuberculosis carcinoma and HIV positive patients including endocrine disorders like Thyrotoxicosis Cushing Syndrome etc

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The efficacy of treatment will be assessed on the <br/ ><br>basis of relief in signs and symptoms <br/ ><br>Evaluation of biochemical parameters such as <br/ ><br>FBS, PPBS in both groups along with <br/ ><br>Hematological, Urine routine and microscopic <br/ ><br>examination before and after the treatment. S. <br/ ><br>Insulin and Glycosulated haemoglobin before <br/ ><br>and after the treatment.(if possible )Timepoint: The efficacy of treatment will be assessed on the <br/ ><br>basis of relief in signs and symptoms after 2 months of treatment <br/ ><br>Evaluation of biochemical parameters such as <br/ ><br>FBS, PPBS in both groups along with <br/ ><br>Hematological, Urine routine and microscopic <br/ ><br>examination before and after the treatment. S. <br/ ><br>Insulin and Glycosulated haemoglobin before <br/ ><br>and after the treatment.(if possible )

Secondary Outcome Measures